© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Results of Novel Assay Shed Light on Impact of Lecanemab on Neurodegeneration in Alzheimer Disease
January 07, 2025
The first study to quantify lecanemab-captured Aβ-PF species in human CSF shows a strong correlation with neurodegeneration and may help explain the drug's MOA.
9 Fast Fact about Avian Influenza for Primary Care
January 07, 2025
The bird flu threat remains low, according to public health authorities, but awareness and vigilance will help keep it that way. Here are 9 things you need to know.
Bird Flu: First US Death Reported, NIH Updates Risk Assessment
January 07, 2025
The first death of an American from the H5N1 virus was reported in Louisiana on Monday, though authorities maintain the risk of widespread infection remains low.
The Electrical Origins of Migraine May be Under the Microscope, Neurologist Peter McAllister, MD, Explains
January 07, 2025
The onset of migraine with its wide range of symptoms may be telegraphed as early as 2 days before by the frequency of neuronal oscillation deep in the brain.
Neumora Therapeutics Reports Disappointing Results from Phase 3 Study of Navacaprant in MDD
January 03, 2025
The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.
Expert Perspectives 2024: Treatment for Agitation in Alzheimer Disease with George Grossberg, MD
January 03, 2025
Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.
Novel Nonopioid Dual Action Analgesic Highly Effective Against Post-Surgical Pain in Phase 2b Trial
January 02, 2025
The new chemical entity from Xgene Pharmaceuticals, XG005, targets both anti-nociceptive and anti-neuropathic pain pathways.
For Alzheimer Agitation, a Novel, Oral NMDA Inhibitor Could be the Next Targeted Treatment
January 02, 2025
Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.
Axsome Completes Phase 3 Clinical Program with AXS-05 in Alzheimer Disease Agitation
January 02, 2025
Axsome plans to submit a New Drug Application to the FDA in the second half of 2025 that is based on positive results from 4 pivotal phase 3 clinical trails and long-term data.
US Adolescent Substance Use Holding Steady or Declining: Highlights from the 2024 Monitoring the Future Survey
January 02, 2025
Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.